Seroloprevalence of Hepatits G Virus (HGV) in Beta-Thalassemia Patients Jahrom-Iran, 1399

Authors
Masihollah Shakeri 1
Hanieh Razaghzadegan 2
karamatollah Rahmanian 1
Fatemeh Sotoodeh Jahromi 3
Abdolreza Sotoodeh Jahromi 4
1 Research Center for Social determinants of health, Jahrom University of medical sciences, Jahrom, Iran
2 Student Research Committee,Jahrom University of Medical Sciences,Jahrom, Iran
3 Student Research Committee, Jahrom University of Medical Sciences,Jahrom, Iran
4 Zoonoses Research center, Jahrom University of Medical Sciences, Jahrom, Iran
10.22034/pjms.2022.700486
Abstract
Introduction: People who have multiple transfusions, such as Beta-thalassemia patients, are at risk for the hepatitis G
virus (HGV) infection. The aim of the study was the determination of serological prevalence of HGV and its associated factors in beta-thalassemia major patients in Jahrom-Iran.
Materials and Methods: This cross-sectional study, was done on 91 beta-thalassemia patients referring to the thalassemia center, Jahrom-Iran, 2021. Blood samples were collected from the patients and anti-HGV antibodies were evaluated by ELISA methods. Serum levels of ALT, AST, ALP and demographic data were extracted from patients' medical records. Descriptive analysis, X2, and T-test were used for statistical analyses by SPSS-16.
Results: The prevalence anti-HGV IgG and IgM were 18.7 % and 5.5 %, respectively. There were significant relationships between the frequencies of anti-HGV antibodies and serum level of ALT, ASL, ALP and also with the history time of transfusion (P<0.05). But, there were no significant relationships between the frequencies of anti-HGV antibodies with patients' sex and the mean of age (P>0.05).
Conclusions: HGV is one of the etiologic factors of hepatitis in thalassemia patients in Jahrom. Further comprehensive and molecular-based studies are recommended to explore the prevalence of HGV and its role in hepatitis thalassemia patients.
Keywords
Hepatitis G virus (HGV)
Sero-Prevalence
Thalassemia
Iran
References 1. AMINI KS, Samiei S, Talebian A, MAGHSOUDLOU M, GHARAH BA. Hepatitis G virus infection in Iranian blood donors and high-risk groups. 2009. 2. Desai MM, Pal RB, Banker DD. GB virus C/hepatitis G virus infection in Indian blood donors and high-risk groups. Transfusion and apheresis science. 2004;30(2):111-7. 3. Yaghobi R, Afkari R, Mohsenzadeh M, Jafari M, Khorrami H, Pirouzi A. A study on the serologic and molecular prevalence of hepatitis G virus (HGV) and hepatitis C virus (HCV) infections in patients with thalassemia in Larestan of Iran. African Journal of Microbiology Research. 2012;6(29):5866-70. 4. Viazov S, Riffelmann M, Sarr S, Ballauff A, Meisel H, Roggendorf M. Transmission of GBV-C/HGV from drug-addicted mothers to their babies. Journal of hepatology. 1997;27(1):85-90. 5. Ebadi M, Yaghobi R, Geramizadeh B, Bahmani M, Malek-Hosseini S, Nemayandeh M, editors. Prevalence of HCV and HGV infections in Iranian liver transplant recipients. Transplantation proceedings; 2011: Elsevier. 6. Frey SE, Homan SM, Sokol-Anderson M, Cayco MT, Cortorreal P, Musial CE, et al. Evidence for probable sexual transmission of the hepatitis G virus. Clinical infectious diseases. 2002;34(8):1033-8. 7. Khodaei GH, Farbod N, Zarif B, Nateghi S, Saeidi M. Frequency of thalassemia in Iran and Khorasan Razavi. International journal of Pediatrics. 2013;1(1):45-50. 8. Moatter T, Adil S, Haroon S, Azeemuddin S, Hassan F, Khurshid M. Prevalence of hepatitis G virus in Pakistani children with transfusion dependent beta-thalassemia major. Indian journal of pathology & microbiology. 1999;42(4):475-82. 9. Organization WH. Regional status report on blood safety and availability 2016. World Health Organization. Regional Office for the Eastern Mediterranean; 2017. 10. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis. 2006;1:23-61. 11. Leary TP, Muerhoff S, Simons JN, Pilot‐Matias TJ, Erker JC, Chalmers ML, et al. Sequence and genomic organization of GBV‐C: A novel member of the Flaviviridae associated with human non‐A‐E hepatitis. Journal of medical virology. 1996;48(1):60-7. 12. Simons JN, Pilot-Matias TJ, Leary TP, Dawson GJ, Desai SM, Schlauder GG, et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proceedings of the National academy of Sciences. 1995;92(8):3401-5. 13. Schlauder GG, Dawson GJ, Simons JN, Pilot‐Matias TJ, Gutierrez RA, Heynen CA, et al. Molecular and serologic analysis in the transmission of the GB hepatitis agents. Journal of medical virology. 1995;46(1):81-90. 14. Stapleton JT, Foung S, Muerhoff AS, Bukh J, Simmonds P. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. The Journal of general virology. 2011;92(Pt 2):233. 15. Jarvis L, Davidson F, Hanley J, Yap P, Ludlam C, Simmonds P. Infection with hepatitis G virus among recipients of plasma products. The Lancet. 1996;348(9038):1352-5. 16. Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World journal of clinical cases. 2018;6(13):589. 17. Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood, The Journal of the American Society of Hematology. 2010;116(16):2875-83. 18. Gharehbaghian A, Tavakoli S, Amini Kafiabad S, Zarnani A. Seroepidemiologic HGV in blood donors, haemodialysis patients, haemophiliacs and major* thalassemics with history of liver disease. Scientific Journal of Iran Blood Transfus Organ. 2005;2(5):189-96. 19. Ibrahim MS, Al Hamdani AH. Hepatitis G virus infection and genotypes in Iraqi thalassemia patients. Iraqi Journal of Hematology. 2015;4(1):67. 20. SH HA, NG N, Hasan ME. Hepatitis G Virus Infection among High Risk Population in Diyala Province.